



Jay Michael S. Balagtas

Clinical Associate Professor, Pediatrics - Hematology & Oncology

CLINICAL OFFICE (PRIMARY)

750 Welch RD STE 200

Palo Alto, CA 94304

Tel (650) 723-5535 Fax (650) 723-5231

Bio

CLINICAL FOCUS

- Ped Hematology/Oncology
- Pediatric Hematology-Oncology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Pediatrics - Hematology & Oncology

PROFESSIONAL EDUCATION

- Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2009) CA
- Residency: United States Naval Medical Center San Diego Pediatric Residency (2003) CA
- Medical Education: New York Medical College Registrar (1998) NY
- Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)

Research & Scholarship

CLINICAL TRIALS

- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT, Recruiting
- A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT, Recruiting
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma, Recruiting
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma, Recruiting
- A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma, Recruiting
- Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors, Recruiting
- Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors, Recruiting
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy, Recruiting
- Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia, Recruiting

- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies, Recruiting
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma, Recruiting
- Study of Kidney Tumors in Younger Patients, Recruiting
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia, Not Recruiting
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery, Not Recruiting
- A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL), Not Recruiting
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma, Not Recruiting
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia, Not Recruiting
- Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours, Not Recruiting
- Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement, Not Recruiting
- Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors, Not Recruiting
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia, Not Recruiting
- Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia, Not Recruiting
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors, Not Recruiting
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET, Not Recruiting
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery, Not Recruiting
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma, Not Recruiting
- Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma, Not Recruiting
- Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma, Not Recruiting
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma, Not Recruiting
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Not Recruiting
- Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma, Not Recruiting
- Neuropsychological and Behavioral Testing in Younger Patients With Cancer, Not Recruiting
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas, Not Recruiting
- Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL), Not Recruiting
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma, Not Recruiting
- Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma, Not Recruiting
- Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome, Not Recruiting
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma, Not Recruiting
- Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder, Not Recruiting
- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia, Not Recruiting

- Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors, Not Recruiting
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial), Not Recruiting
- Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial), Not Recruiting
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL), Not Recruiting
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia, Not Recruiting
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations, Not Recruiting
- Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer, Not Recruiting

Publications

PUBLICATIONS

- **P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).**
Mak, B., Tran, B., Pashankar, F. D., Mazhar, D., Huddart, R. A., Wheeler, M., Walpole, E., Feldman, D. R., Dunwoodie, E., Lawrence, N., Birtle, A., Wyld, D., Stevanovic, et al
LIPPINCOTT WILLIAMS & WILKINS.2024: TPS524
- **Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.** *Frontiers in immunology*
Johns, C., Erickson, C., Jacobs, A., Moon, J., Baggott, C., Dagher, R., Nadel, H., Balagtas, J., Aftandilian, C., Ramakrishna, S., Lacayo, N., Davis, K. L., Stieglitz, et al
2024; 15: 1423487
- **A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia**
Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y.
SPRINGER/PLENUM PUBLISHERS.2021: S55
- **P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumors (GCTs).**
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F. D., Tran, B., Jeffery, M., Mazhar, D., Huddart, R. A., Walpole, E., Stevanovic, A., Wyld, D., Hanning, et al
LIPPINCOTT WILLIAMS & WILKINS.2021
- **P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)**
Subramaniam, S., Toner, G. C., Stockler, M. R., Martin, A., Pashankar, F., Tran, B., Jeffery, M., Mazhar, D., Huddart, R., Walpole, E., Stevanovic, A. G., Wyld, D., Hanning, et al
WILEY.2020: 205-206
- **The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: guidance from the SSC of the ISTH** *JOURNAL OF THROMBOSIS AND HAEMOSTASIS*
Tullius, B. P., Athale, U., Van Ommen, C. H., Chan, A. C., Palumbo, J. S., Balagtas, J. S., Subcomm Hemostasis & Malignan, Subcomm Pediat Neonatal Throm
2018; 16 (1): 175–80
- **Rate of abnormal vaginal bleeding and contraception counseling in women undergoing chemotherapy** *JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY*
Cutler, K. E., Creinin, M. D., Balagtas, J. S., Hou, M. Y.
2016; 14 (8): 337–41
- **Subcutaneous Panniculitis-Like T-Cell Lymphoma: Pediatric Case Series Demonstrating Heterogeneous Presentation and Option for Watchful Waiting** *PEDIATRIC BLOOD & CANCER*
Johnston, E. E., LeBlanc, R. E., Kim, J., Chung, J., Balagtas, J., Kim, Y. H., Link, M. P.
2015; 62 (11): 2025-2028

- **Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.** *PLoS genetics*
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J., Sweeney, R. T., Lai, E., Del Vecchio, C. A., Forster, A. D., Clarke, N., Montgomery, K. D., Zhu, et al
2013; 9 (4)
- **Therapeutic Complications in a Patient With High-Risk Acute Lymphoblastic Leukemia and Undiagnosed Hereditary Hemochromatosis** *PEDIATRIC BLOOD & CANCER*
Balagtas, J. M., Dahl, G. V.
2012; 58 (1): 101-103
- **Liposomal amphotericin B associated with severe hyperphosphatemia** *PEDIATRIC INFECTIOUS DISEASE JOURNAL*
Sutherland, S. M., Hong, D. K., Balagtas, J., Gutierrez, K., Dvorak, C. C., Sarwal, M.
2008; 27 (1): 77-79